<DOC>
	<DOCNO>NCT01328379</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy low dose dalfampridine extend release tablet compare currently approve dose improve walk Multiple Sclerosis ( MS ) patient .</brief_summary>
	<brief_title>Study Fampridine-ER Tablets Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The current study design prospective placebo-controlled trial investigate safety efficacy low dose dalfampridine extend release tablet ( 5 mg twice daily ) compare approve commercial dose 10 mg twice daily improve walk MS patient four-week period treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patient clinically definite Multiple Sclerosis define MacDonald Criteria . Patient must 18 70 year age , inclusive ( i.e . 18th birthday , day 71st birthday Screening Visit ) . Patient previously take Ampyra® dalfampridine ( fampridine 4 aminopyridine ; 4AP ) formulation ( include compound ) , must withdraw drug least one month prior Screening Visit . Patient must mentally competent understand sign Internal Review Board ( IRB ) approve informed consent prior performance studyspecific procedure . Patient able perform require study procedure . In judgement Investigator , patient MSrelated walk impairment sufficient ambulatory ability able complete two trial Timed 25 Foot Walk ( T25FW ) screen Visit every study visit thereafter , two trial complete within 5 minute one another accordance specific instruction provide National Multiple Sclerosis Society MS Functional Composite Manual . Patient female childbearing potential ( see Exclusion Criterion 1 definition ) must negative urine pregnancy test Screening Visit . Patient female childbearing potential ( i.e. , hysterectomy bilateral oophorectomy , least two year postmenopausal ) , engage active heterosexual relation use one follow birth control method : tubal ligation , implantable contraception device , oral , patch injectable contraceptive , double barrier method , sexual activity restrict vasectomized partner . Patient pregnant breastfeeding . Patient history seizure . Patient moderate severe renal impairment define calculated creatinine clearance ≤ 50 mL/minute . Patient active urinary tract infection ( UTI ) Screening within 4 week Screening . Patient onset ( assessed treat physician ) MS exacerbation within 60 day prior Screening Visit . Patient start concomitant prescription medication regimen within last three week , and/or concomitant medication regimen expect change course study . Patient receive cyclophosphamide ( Cytoxan ) mitoxantrone ( Novantrone ) MS treatment within six month prior Screening Visit . Patient start treatment regimen Betaseron , Avonex , Copaxone , Rebif , Tysabri , Extavia Gilenya™ within 90 day prior Screening Visit change dose regimen drug within 30 day prior Screening Visit . Patient receive corticosteroid ( topical preparation ) within 30 day prior Screening Visit and/or expect receive regularly schedule corticosteroid treatment course study . Patient administer botulinum toxin low extremity within six month prior Screening Visit and/or expect receive botulinum toxin low extremity course study . Patient know allergy pyridinecontaining substance inactive ingredient dalfampridine tablet ( colloidal silicon dioxide , hydroxypropyl methylcellulose , magnesium stearate , microcrystalline cellulose , polyethylene glycol , titanium dioxide ) . Patient history drug alcohol abuse within past year . Patient clinically significant abnormal laboratory value . Patient angina , uncontrolled hypertension , clinically significant cardiac arrhythmia , clinically significant cardiovascular abnormality . Patient medical condition ( include psychiatric disease ) would interfere interpretation study result conduct study . Patient participate investigational trial 30 day prior Screening Visit plan enroll another investigational trial time study . Nondrug ( i.e . observational , registry ) non medical device trial allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>